文献速递艾滋病与性传播感染结核与非结核分枝杆菌病毒性肝炎

HIV-TB合并感染者抗结核治疗中药物性肝损伤高发:START TB试验结果

High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究为START TB随机试验的事后分析,纳入642例HIV-TB合并感染者,随机分为早期、晚期或TB治疗结束后启动ART。结果显示抗结核治疗开始后肝损伤发生率高,且与ART启动时机无关;高龄和乙肝阳性预测肝损伤。

要点

  • HIV-TB合并感染者抗结核治疗中肝损伤发生率高。
  • 肝损伤发生率在不同ART启动时机组间无显著差异。
  • 高龄和乙肝阳性是肝损伤的预测因素。

核心结论

  • HIV-TB合并感染者抗结核治疗期间肝损伤发生率高,与ART启动时机无关。

研究设计与样本

  • 随机对照试验START TB的事后分析,纳入642例患者,随机分为早期、晚期或TB治疗结束后启动ART。

主要发现

  • 642例患者中位年龄34岁(标准差28-40),17.6%基线CD4+细胞计数<50 cells/mm3。
  • 472例患者中146例在TB治疗开始后出现新发肝损伤(早期、晚期、序贯组分别为52、47、47例)。
  • CD4+<200 cells/mm3患者ART启动后肝损伤发生率在早期、晚期整合、序贯组分别为27.4(95%CI 18.0-39.8)、19.0(95%CI 10.9-30.9)、18.4(95%CI 8.8-33.8)/100人年。
  • CD4+≥200 cells/mm3患者相应发生率分别为32.1(95%CI 20.1-48.5)、11.8(95%CI 4.3-25.7)、28.2(95%CI 13.5-51.9)/100人年。
  • 严重及危及生命的肝损伤在早期、晚期、序贯组分别发生2、7、3例;高龄和乙肝阳性预测肝损伤。

临床怎么用

  • 临床应重视HIV-TB合并感染者抗结核治疗期间的肝功能监测。

局限性

  • 本研究为事后分析,可能受原始试验设计限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New onset or worsening drug-induced liver injury challenges coinfected patients on antiretroviral therapy (ART) initiation during antituberculosis (TB) treatment. METHODS: Post hoc analysis within a randomized trial, the Starting Antiretroviral Therapy at Three Points in Tuberculosis trial, was conducted. Patients were randomized to initiate ART either early or late during TB treatment or after TB treatment completion. Liver enzymes were measured at baseline, 6-month intervals, and when clinically indicated. RESULTS: Among 642 patients enrolled, the median age was 34 years (standard deviation, 28-40), and 17.6% had baseline CD4+ cell counts <50 cells/mm3. Overall, 146/472 patients (52, 47, and 47: early, late, and sequential arms) developed new-onset liver injury following TB treatment initiation. The incidence of liver injury post-ART initiation in patients with CD4+ cell counts <200 cells/mm3 and ≥200 cells/ mm3 was 27.4 (95% confidence interval [CI], 18.0-39.8), 19.0 (95% CI, 10.9-30.9), and 18.4 (95% CI, 8.8-33.8) per 100 person-years, and 32.1 (95% CI, 20.1-48.5), 11.8 (95% CI, 4.3-25.7), and 28.2 (95% CI, 13.5-51.9) per 100 person-years in the early, late integrated, and sequential treatment arms, respectively. Severe and life-threatening liver injury occurred in 2, 7, and 3 early, late, and sequential treatment arm patients, respectively. Older age and hepatitis B positivity predicted liver injury. CONCLUSIONS: High incidence rates of liver injury among cotreated human immunodeficiency virus (HIV)-TB coinfected patients were observed. Clinical guidelines and policies must provide guidance on frequency of liver function monitoring for HIV-TB coinfected patients.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Naidoo K, Hassan-Moosa R, Mlotshwa P, et al. High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial. Clin Infect Dis. 2020. PMID: 31622456. doi:10.1093/cid/ciz732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。